194 related articles for article (PubMed ID: 38495100)
1. Neutrophil elastase as a versatile cleavage enzyme for activation of αvβ3 integrin-targeted small molecule drug conjugates with different payload classes in the tumor microenvironment.
Rebstock AS; Wiedmann M; Stelte-Ludwig B; Wong H; Johnson AJ; Izumi R; Hamdy A; Lerchen HG
Front Pharmacol; 2024; 15():1358393. PubMed ID: 38495100
[No Abstract] [Full Text] [Related]
2. Discovery of VIP236, an αvβ3-Targeted Small-Molecule-Drug Conjugate with Neutrophil Elastase-Mediated Activation of 7-Ethyl Camptothecin Payload for Treatment of Solid Tumors.
Lerchen HG; Stelte-Ludwig B; Heroult M; Zubov D; Gericke KM; Wong H; Frigault MM; Johnson AJ; Izumi R; Hamdy A
Cancers (Basel); 2023 Sep; 15(17):. PubMed ID: 37686656
[TBL] [Abstract][Full Text] [Related]
3. A Small Molecule-Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an α
Lerchen HG; Stelte-Ludwig B; Kopitz C; Heroult M; Zubov D; Willuda J; Schlange T; Kahnert A; Wong H; Izumi R; Hamdy A
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053556
[TBL] [Abstract][Full Text] [Related]
4. Optimizing the enzymatic release of MMAE from
Zambra M; Ranđelović I; Talarico F; Borbély A; Svajda L; Tóvári J; Mező G; Bodero L; Colombo S; Arrigoni F; Fasola E; Gazzola S; Piarulli U
Front Pharmacol; 2023; 14():1215694. PubMed ID: 37492088
[TBL] [Abstract][Full Text] [Related]
5. In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment.
Bocci M; Zana A; Principi L; Lucaroni L; Prati L; Gilardoni E; Neri D; Cazzamalli S; Galbiati A
J Control Release; 2024 Mar; 367():779-790. PubMed ID: 38346501
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.
Dal Corso A; Caruso M; Belvisi L; Arosio D; Piarulli U; Albanese C; Gasparri F; Marsiglio A; Sola F; Troiani S; Valsasina B; Pignataro L; Donati D; Gennari C
Chemistry; 2015 Apr; 21(18):6921-9. PubMed ID: 25784522
[TBL] [Abstract][Full Text] [Related]
7. Mono-amino acid linkers enable highly potent small molecule-drug conjugates by conditional release.
Zheng Y; Xu R; Cheng H; Tai W
Mol Ther; 2024 Apr; 32(4):1048-1060. PubMed ID: 38369752
[TBL] [Abstract][Full Text] [Related]
8. PSMA-targeted small-molecule drug-conjugates with valine-citrulline and phosphoramidate cleavable linkers.
Savoy EA; Olatunji FP; Fulton MD; Kesic BN; Herman JW; Romero O; Maniatopoulos M; Berkman CE
Bioorg Med Chem Lett; 2024 Jan; 98():129573. PubMed ID: 38052377
[TBL] [Abstract][Full Text] [Related]
9. Dual intra- and extracellular release of monomethyl auristatin E from a neutrophil elastase-sensitive antibody-drug conjugate.
Mohamed Amar IA; Huvelle S; Douez E; Letast S; Henrion S; Viaud-Massuard MC; Aubrey N; Allard-Vannier E; Joubert N; Denevault-Sabourin C
Eur J Med Chem; 2022 Feb; 229():114063. PubMed ID: 34974337
[TBL] [Abstract][Full Text] [Related]
10. Linker Architectures as Steric Auxiliaries for Altering Enzyme-Mediated Payload Release from Bioconjugates.
Giese M; Davis PD; Woodman RH; Hermanson G; Pokora A; Vermillion M
Bioconjug Chem; 2021 Oct; 32(10):2257-2267. PubMed ID: 34587447
[TBL] [Abstract][Full Text] [Related]
11. Small Molecule-Drug Conjugates: Opportunities for the Development of Targeted Anticancer Drugs.
Zhang J; Hu F; Aras O; Chai Y; An F
ChemMedChem; 2024 Jun; 19(11):e202300720. PubMed ID: 38396351
[TBL] [Abstract][Full Text] [Related]
12. Small molecule- and peptide-drug conjugates addressing integrins: A story of targeted cancer treatment.
Paulus J; Sewald N
J Pept Sci; 2024 Jul; 30(7):e3561. PubMed ID: 38382900
[TBL] [Abstract][Full Text] [Related]
13. Conjugates of Cryptophycin and RGD or
Borbély A; Figueras E; Martins A; Bodero L; Raposo Moreira Dias A; López Rivas P; Pina A; Arosio D; Gallinari P; Frese M; Steinkühler C; Gennari C; Piarulli U; Sewald N
ChemistryOpen; 2019 Jun; 8(6):737-742. PubMed ID: 31275795
[TBL] [Abstract][Full Text] [Related]
14. Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody-Drug Conjugates.
Chuprakov S; Ogunkoya AO; Barfield RM; Bauzon M; Hickle C; Kim YC; Yeo D; Zhang F; Rabuka D; Drake PM
Bioconjug Chem; 2021 Apr; 32(4):746-754. PubMed ID: 33689309
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Evaluation of a Non-Peptide Small-Molecule Drug Conjugate Targeting Integrin α
Paulus J; Sewald N
Front Chem; 2022; 10():869639. PubMed ID: 35480387
[TBL] [Abstract][Full Text] [Related]
16. Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment.
Zhuang C; Guan X; Ma H; Cong H; Zhang W; Miao Z
Eur J Med Chem; 2019 Feb; 163():883-895. PubMed ID: 30580240
[TBL] [Abstract][Full Text] [Related]
17. αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology.
Dal Corso A; Pignataro L; Belvisi L; Gennari C
Curr Top Med Chem; 2016; 16(3):314-29. PubMed ID: 26126915
[TBL] [Abstract][Full Text] [Related]
18. Tailored Linker Chemistries for the Efficient and Selective Activation of ADCs with KSPi Payloads.
Lerchen HG; Stelte-Ludwig B; Sommer A; Berndt S; Rebstock AS; Johannes S; Mahlert C; Greven S; Dietz L; Jörißen H
Bioconjug Chem; 2020 Aug; 31(8):1893-1898. PubMed ID: 32667786
[TBL] [Abstract][Full Text] [Related]
19. Antibody drug conjugates beyond cytotoxic payloads.
Hobson AD
Prog Med Chem; 2023; 62():1-59. PubMed ID: 37981349
[TBL] [Abstract][Full Text] [Related]
20. Lysosomal-Cleavable Peptide Linkers in Antibody-Drug Conjugates.
Balamkundu S; Liu CF
Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
